Union City, CA, United States of America

Mei Huang


Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 3(Granted Patents)


Location History:

  • Menlo Park, CA (US) (2013)
  • Union City, CA (US) (2014)

Company Filing History:


Years Active: 2013-2014

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Innovations in Gene Therapy by Mei Huang

Introduction

Mei Huang is a prominent inventor based in Union City, CA (US). She has made significant contributions to the field of gene therapy, particularly in the treatment of ischemic heart disease. With a total of 2 patents, her work focuses on innovative approaches to enhance cardiovascular health.

Latest Patents

One of Mei Huang's latest patents involves shRNA gene therapy for the treatment of ischemic heart disease. This therapy utilizes short hairpin RNA (shRNA) interference targeting hypoxia-inducible factor-1 alpha (HIF-1α) prolyl-4-hydroxylase protein (HIF-PHD2) to treat myocardial ischemia. The treatment can be monitored noninvasively through molecular imaging. Additionally, she has developed compositions that include novel vectors encoding shRNA targeting the HIF-1α and asparaginyl hydroxylase genes. These vectors are also beneficial for treating cardiac diseases, peripheral vascular diseases, and decubitus ulcers.

Another significant patent focuses on the use of minicircle vectors for cardiac gene therapy. This invention provides compositions and methods for treating ischemic cardiovascular conditions by administering a novel non-viral minicircle DNA vector. This vector comprises polynucleotide sequences that enhance HIF-1 activity, including RNAi or antisense agents selective for proteins involved in HIF-1 inactivation.

Career Highlights

Mei Huang is affiliated with Leland Stanford Junior University, where she continues her research and development in gene therapy. Her innovative work has positioned her as a key figure in the advancement of treatments for cardiovascular diseases.

Collaborations

Mei Huang collaborates with esteemed colleagues such as Joseph C Wu and Mark A Kay, further enhancing her research capabilities and contributions to the field.

Conclusion

Mei Huang's innovative work in gene therapy represents a significant advancement in the treatment of ischemic heart disease. Her patents and research continue to pave the way for new therapeutic approaches in cardiovascular health.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…